ABL Bio
Privately held: no public share price · South Korea
Assets
(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
| Target & Modality | |||
|---|---|---|---|
| Phase 2 | Claudin 18.2 (CLDN18.2) x 4-1BBMultispecific antibody | Gastric Cancer |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2030 (1)
March 2030 (1)
givastomigPhase 2Solid Tumor, Advanced Cancer, Metastatic Cancer, Gastric Cancer, Gastroesophageal Junction Carcinoma, Esophageal Adenocarcinoma
Est. primary completion 2030-03 · NCT07432295 · CT.gov ↗
What to watch
Financial reports
No financial reports recorded.